tradingkey.logo

Bluejay Diagnostics Inc

BJDX
View Detailed Chart

1.460USD

-0.060-3.95%
Close 09/19, 16:00ETQuotes delayed by 15 min
2.18MMarket Cap
LossP/E TTM

Bluejay Diagnostics Inc

1.460

-0.060-3.95%
Intraday
1m
30m
1h
D
W
M
D

Today

-3.95%

5 Days

-7.01%

1 Month

+12.31%

6 Months

-64.39%

Year to Date

-70.02%

1 Year

-80.84%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
278 / 506
Overall Ranking
466 / 4720
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 267.47.
Overvalued
The company’s latest PE is 0.00, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 13.33K shares, decreasing 45.71% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
Ticker SymbolBJDX
CompanyBluejay Diagnostics Inc
CEOMr. Neil (Indranil) Dey
Websitehttps://bluejaydx.com/
KeyAI